DYNAGLIPT TAB 10.S

About

DYNAGLIPT TAB is an oral antidiabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It works by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are naturally released by the intestine in response to food. These hormones stimulate the pancreas to release insulin when blood glucose levels are high and suppress the secretion of glucagon, a hormone that raises blood sugar. By enhancing the body's natural ability to control blood glucose, DYNAGLIPT TAB helps to improve glycemic control in patients with Type 2 Diabetes Mellitus. It is used as an adjunct to diet and exercise, either alone or in combination with other antidiabetic agents, to achieve target blood sugar levels and reduce the risk of diabetes-related complications.

Uses

• Treatment of Type 2 Diabetes Mellitus.
• As an adjunct to diet and exercise.
• Used alone or in combination with other antidiabetic agents.
• To improve glycemic control in adults.

Directions For Use

Take orally once daily, with or without food, as prescribed by your healthcare provider.

Benefits

• Effective blood sugar reduction.
• Low risk of hypoglycemia when used as monotherapy.
• Weight-neutral effect.
• Convenient once-daily dosing.
• Improves both fasting and post-meal glucose.
• Generally well-tolerated.

Side Effects

• Nasopharyngitis
• Headache
• Upper respiratory tract infection
• Diarrhea
• Joint pain (arthralgia)
• Hypoglycemia (especially with sulfonylureas or insulin)
• Pancreatitis (rare)
• Allergic reactions (e.g., rash, urticaria)
• Angioedema
• Bullous pemphigoid (rare)
• Constipation
• Dizziness

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake should be avoided as it can affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy due to insufficient data on human safety. Use only if potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if this medication is excreted in human milk. A decision should be made whether to discontinue nursing or discontinue the drug.
• Liver - Generally considered safe for use in patients with mild to moderate hepatic impairment. No dose adjustment is typically required.
• Kidney - Dose adjustment may be required depending on the specific gliptin and the degree of renal impairment. Some gliptins (e.g., Linagliptin) do not require dose adjustment.
• Lung - No specific contraindications or dose adjustments related to lung conditions. Use with caution in patients with a history of pancreatitis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.